7PL Stock Overview
A medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ProstaLund AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0002 |
| 52 Week High | SEK 0.15 |
| 52 Week Low | SEK 0.0002 |
| Beta | 0.55 |
| 11 Month Change | 0% |
| 3 Month Change | -98.08% |
| 1 Year Change | -99.85% |
| 33 Year Change | -99.96% |
| 5 Year Change | n/a |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7PL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -75.0% | -1.0% | -0.02% |
| 1Y | -99.9% | -7.3% | 8.2% |
Return vs Industry: 7PL underperformed the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: 7PL underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 7PL volatility | |
|---|---|
| 7PL Average Weekly Movement | 4,979.7% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7PL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7PL's weekly volatility has increased from 2588% to 4980% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 9 | Anders Kristensson | prostalund.se |
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow soft stent; Oruflow, a urine flow meter; Dosi-Fuser, a disposable continuous infusion system; and Dosi-Flow, a gravitation unit with a flow regulator for dosing of medicines. The company also provides Schelin Catheter, an injection tool that allows the urologists to administer drugs into the prostate in a sterile way through the urethra.
ProstaLund AB (publ) Fundamentals Summary
| 7PL fundamental statistics | |
|---|---|
| Market cap | €2.58m |
| Earnings (TTM) | -€1.73m |
| Revenue (TTM) | €1.42m |
1.8x
P/S Ratio-1.5x
P/E RatioIs 7PL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7PL income statement (TTM) | |
|---|---|
| Revenue | SEK 16.34m |
| Cost of Revenue | SEK 4.86m |
| Gross Profit | SEK 11.48m |
| Other Expenses | SEK 31.42m |
| Earnings | -SEK 19.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 20, 2025
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 70.29% |
| Net Profit Margin | -122.04% |
| Debt/Equity Ratio | 1.8% |
How did 7PL perform over the long term?
See historical performance and comparison